Article
Androgen receptor signaling in androgen-refractory prostate cancer.
Journal of the National Cancer Institute - 21 Nov 2001
Grossmann M E, Huang H, Tindall D J
Abstract excerpt
Prostate cancer is the second most prevalent cancer in males in the United States. Standard therapy relies on removing, or blocking the actions of, androgens. In most cases, this therapy results in a regression of the cancer because the prostate and most primary prostate tumors depend on androgens for growth and the avoidance of apoptosis. However, a portion of the cancers eventually relapse, at which point they...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.